Hemo China Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
156
- Latest Deal Type
-
IPO
- (Cancelled)
- Investors
-
9
Hemo China General Information
Description
Manufacturer, provider and developer of innovative interventional medical devices designed for cerebrovascular diseases. The company focuses on research in the field of minimally invasive interventional treatment of vascular diseases, and provides overall neuro-intervention solutions for ischemic stroke, hemorrhagic stroke and intracranial vascular stenosis, enabling patients with interventional medical devices.
Contact Information
Website
www.hemocorp.comCorporate Office
- Floor 6M, Building 5, District 4, Hanwei International Plaza
- Fengtai District
- Beijing
- China
Corporate Office
- Floor 6M, Building 5, District 4, Hanwei International Plaza
- Fengtai District
- Beijing
- China
Hemo China Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. IPO | 25-Aug-2022 | Cancelled | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 05-Jan-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 10-Oct-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 25-Apr-2020 | $11.5M | $21.5M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 22-Sep-2017 | $27M | $10M | Completed | Generating Revenue |
Hemo China Comparisons
Industry
Financing
Details
Hemo China Competitors (1)
One of Hemo China’s competitors is Meril Life Sciences, a Private Equity-Backed company based in Vapi, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Meril Life Sciences | Private Equity-Backed | Vapi, India |
Hemo China Signals
Hemo China Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hudson Bay Capital Management | Asset Manager | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority | ||
| Octagon Capital Advisors | Hedge Fund | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Trustbridge Partners | Growth/Expansion | Minority |
Hemo China FAQs
-
When was Hemo China founded?
Hemo China was founded in 2016.
-
Where is Hemo China headquartered?
Hemo China is headquartered in Beijing, China.
-
What is the size of Hemo China?
Hemo China has 156 total employees.
-
What industry is Hemo China in?
Hemo China’s primary industry is Surgical Devices.
-
Is Hemo China a private or public company?
Hemo China is a Private company.
-
What is Hemo China’s current revenue?
The current revenue for Hemo China is .
-
How much funding has Hemo China raised over time?
Hemo China has raised $121M.
-
Who are Hemo China’s investors?
Hudson Bay Capital Management, LAV (Lilly Asia Fund), Octagon Capital Advisors, OrbiMed, and Trustbridge Partners are 5 of 9 investors who have invested in Hemo China.
-
Who are Hemo China’s competitors?
Meril Life Sciences is a competitor of Hemo China.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process